← Sulfonylureas & glinides × all-cause mortality

SynthesisBMC endocrine disorders2022

Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.

Vallo Volke et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 26,204 people · 2022

Not counted

Increased deaths

+32%+7% to +61%

Bigger than 7 in 10 for all-cause mortality

As reported

OR 1.32, 95% CI 1.07–1.61 · the paper's word: All-cause mortality

Range includes no effect

No clear effect on deaths

+32%+0% to +75%

Bigger than 7 in 10 for all-cause mortality

As reported

OR 1.32, 95% CI 1.00–1.75 · the paper's word: All-cause mortality

Not counted

Increased cardiovascular events

1.7×1.2× to 2.4×

Bigger than 8 in 10 for cardiovascular events

As reported

OR 1.67, 95% CI 1.17–2.38

Not counted

Increased cardiovascular events

5.2×4.2× to 6.5×

Bigger than almost all for cardiovascular events

As reported

OR 5.24, 95% CI 4.20–6.55

Four numbers in the abstract

the abstract, start to end

… higher odds for all-cause mortality (OR 1.32, 95% CI 1.00-1.75), MACE (OR 1.32, 95% CI 1.07-1.61), myocardial infarction (fatal and non-fatal) (OR 1.67, 95% CI 1.17-2.38) and hypoglycaemia (OR 5.24, 95% CI 4.20-6.55).

← favours treatmentfavours comparator →

could be chance

All-cause mortality

OR 1.321.07–1.61

All-cause mortality

OR 1.321.00–1.75

Cardiovascular events

OR 1.671.17–2.38

Cardiovascular events

OR 5.244.20–6.55

Sulfonylureas & glinidesCardiovascular eventsAll-cause mortality

1 / 3

11 papers cite it

2022

2023

2024

2025

2026

this papercites it

Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.

What the trial testedas reported · 26,204 people · 2022

Increased deaths

No clear effect on deaths

Increased cardiovascular events

Increased cardiovascular events

Four numbers in the abstract

Where each one falls

Where it lands on the map

11 papers cite it